Vasilopoulou Elisavet, Winyard Paul J D, Riley Paul R, Long David A
UCL Institute of Child Health, Developmental Biology and Cancer , 30 Guilford Street, London, WC1N 1EH , UK +44 207 905 2615 ; +44 207 905 2133 ;
Expert Opin Biol Ther. 2015;15 Suppl 1:S187-90. doi: 10.1517/14712598.2015.1009891. Epub 2015 Jun 22.
Therapies that modulate inflammation and fibrosis have the potential to reduce the morbidity and mortality associated with chronic kidney disease (CKD). A promising avenue may be manipulating thymosin-β4, a naturally occurring peptide, which is the major G-actin sequestering protein in mammalian cells and a regulator of inflammation and fibrosis. Thymosin-β4 is already being tested in clinical trials for heart disease and wound healing. This editorial outlines the evidence that thymosin-β4 may also have therapeutic benefit in CKD.
调节炎症和纤维化的疗法有可能降低与慢性肾脏病（CKD）相关的发病率和死亡率。一个有前景的途径可能是操控胸腺素β4，一种天然存在的肽，它是哺乳动物细胞中主要的G-肌动蛋白隔离蛋白以及炎症和纤维化的调节因子。胸腺素β4已在心脏病和伤口愈合的临床试验中进行测试。这篇社论概述了胸腺素β4在CKD中也可能具有治疗益处的证据。
